已收盘 08-01 16:00:00 美东时间
+0.010
+0.49%
Elutia Inc. will release its second-quarter 2025 financial results after market close on August 14, 2025. A conference call and webcast detailing the results will be held that day at 5:00 p.m. ET / 2:00 p.m. PT. U.S. investors can dial 877-407-8029, while international investors can dial 201-689-8029, both using conference ID: 13754773. The event will be webcast live and archived on Elutia's investor website. Elutia specializes in drug-eluting bi...
07-31 20:05
Elutia Inc. announced that its Chief Scientific Officer, Dr. Michelle LeRoux Williams, received the Medical Device Innovator Award for her leadership in developing EluPro™, the first FDA-cleared antibiotic-eluting bioenvelope for cardiac implantable electronic devices. EluPro addresses complications like infection and erosion, affecting up to 5-7% of CIEDs implanted annually in the U.S. Dr. Williams emphasized the collaborative effort in bringi...
07-31 12:00
Elutia Inc. announced a study published in the *Journal of Functional Biomaterials* showcasing the bioactive properties of its EluPro BioEnvelope for CIEDs. The study highlights that EluPro reduces inflammation, promotes vascularization, and minimizes fibrosis, leading to healthier device pockets and lower infection risks. Unlike synthetic materials, EluPro demonstrated long-term benefits in reducing inflammation and scarring over 26 weeks. Resea...
07-01 12:00
Elutia Inc. has been honored with two 2025 Medical Device Network Excellence Awards for Innovation and Product Launches, recognizing its EluPro™ Antibiotic-Eluting BioEnvelope. Launched in January 2025, EluPro addresses complications in cardiac implantable electronic devices (CIEDs) and neurostimulators by combining antibiotics with a regenerative biomatrix. Since its pilot launch in September 2024, EluPro has achieved an 84% sequential sales inc...
06-26 12:00
Elutia Inc. has announced the publication of a novel method for measuring antibiotic release from biologic envelopes, published in *Dissolution Technologies*. This method offers faster, cost-effective development and testing of their EluPro portfolio, capturing the biphasic release profile of antibiotics. EluPro, an antibiotic-eluting bioenvelope for cardiac implants and neurostimulators, was commercially launched in January 2025, supporting heal...
05-28 12:00
潜在涨幅754.7%!HC Wainwright & Co.:Alector获机构升目标价至10美元,维持"买入"评级
05-10 10:00
Lake Street analyst Frank Takkinen maintains Elutia (NASDAQ:ELUT) with a Buy and lowers the price target from $10 to $8.
05-09 23:01
Companies Reporting Before The Bell • Sempra (NYSE:SRE) is likely to report qua...
05-08 16:33
An update from Aziyo Biologics ( ($ELUT) ) is now available. On April 30, 2025,...
05-07 05:15
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1105190809351499777.png</p><span style="color:#999999;">编者按:每日追踪华尔街最新评级与目标价,挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• RBC Capital:维持Canadian Natural Res(CNQ)"跑赢大市"评级,目标价从62美元升至63美元</p> <p>• 摩根大通:维持Carvana(CVNA)"超配"评级,目标价从350美元升至3
03-10 10:29